The capital will be used for the final study required before launch in the veterinary market of Immuvera Therapeutics’ innovative treatment for cancer in the lungs, initially in dogs.

In this round, the company will raise between NOK 7.0 and 17.9 million at a price per share of NOK 19.50. The pre-money market capitalization is NOK 127.3 million.

Prior to this financing round, Immuvera has raised a total of NOK 45 million, about half of which was raised through Folkeinvest.

This equity round is, for regulatory reasons, only available to investors in Norway and Sweden. 

The upcoming study will take the company from clinical development to strategic partnerships, acquisition, or public listing.

“This is no longer research, but the final stage before launching a new pharmaceutical product into the world,” said Jørund Sollid, CEO of Immuvera Therapeutics.

You can read more about our solution here